AChE/BChE-IN-37

AChE/BChE-IN-37 (multiple concentration gradients; 15 min compound + enzyme, 10 min substrate addition) potently inhibits electric eel-derived AChE with an IC₅₀ of 73.65 μM^[1].
AChE/BChE-IN-37 (multiple concentration gradients; 15 min compound + enzyme, 10 min substrate addition) inhibits horse serum-derived BChE with an IC₅₀ of 82.93 μM^[1].
AChE/BChE-IN-37 (25 μM; 24 h) inhibits Aβ₁-4₂ aggregation by 35.30% at a concentration of 25 μM^[1].
AChE/BChE-IN-37 (25-200 μM; 24 h) shows no significant cytotoxicity in BV2 cells at concentrations up to 150 μM, with mild cytotoxicity observed at 200 μM^[1].
AChE/BChE-IN-37 (25 μM; 3 h) exhibits chelating abilities with Cu²⁺, Ca²⁺, Mg²⁺, Fe²⁺, and Zn²⁺ ions^[1].
AChE/BChE-IN-37 (25-200 μM; 24 h pre-incubation, 24 h LPS stimulation) potently inhibits LPS-induced NO production in BV2 cells with an IC₅₀ of 31.42 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.